Jazz Pharmaceuticals (JAZZ) PT Raised to $176 at Morgan Stanley on Xyrem and Xywav
Tweet Send to a Friend
Morgan Stanley analyst David Risinger raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $176.00 (from $162.00) on expected ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
